Study of Sorption Technology Added to Standard Hemodialysis for Adults with Chronic Kidney Disease and Inflammation

What this Trial Is About

Researchers are evaluating the use of sorption technologies in patients undergoing maintenance hemodialysis who have inflammatory syndrome and symptoms of uremia. This study involves 30 hemodialysis patients selected based on elevated levels of C-reactive protein CRP andor interleukin-6 IL-6. The purpose is to assess changes in inflammatory markers and other blood parameters over a three-month period while undergoing this treatment. Participants will receive hemoadsorption using the Jafron HA130 cartridge alongside their regular hemodialysis sessions. The combined hemodialysis and hemoadsorption will be performed three times weekly during the first month, twice weekly in the second month, and once weekly in the third month. Another group will continue with the standard hemodialysis procedure for comparison. Throughout the study, blood tests will measure inflammatory markers such as CRP, IL-1, IL-6, IL-8, and others, along with parathyroid hormone and standard biochemical tests. These assessments will be done before starting and monthly for three months. Researchers will monitor changes in these markers, as well as quality-of-life measures like anxiety, depression, and pruritus. The primary outcome is the change in IL-6 levels by the third month, with ongoing safety and efficacy monitoring during this time.

Studies on Adsorption International Learning Initiative Global